X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (57) 57
index medicus (56) 56
life sciences (42) 42
female (40) 40
pharmacokinetics (38) 38
male (37) 37
pharmacology & pharmacy (37) 37
adult (32) 32
middle aged (32) 32
pharmaceutical sciences (24) 24
pharmacology (23) 23
aged (22) 22
antibodies, monoclonal - pharmacokinetics (18) 18
monoclonal antibodies (18) 18
rituximab (18) 18
human health and pathology (17) 17
infliximab (17) 17
dose-response relationship, drug (16) 16
population pharmacokinetics (16) 16
antibodies, monoclonal - administration & dosage (14) 14
rheumatoid arthritis (14) 14
therapeutic drug monitoring (13) 13
cancer (12) 12
rheumatoid-arthritis (12) 12
arthritis, rheumatoid - drug therapy (11) 11
crohns-disease (11) 11
models, biological (11) 11
prospective studies (11) 11
antibodies (10) 10
clinical-response (10) 10
oncology (10) 10
toxicology (10) 10
animals (9) 9
efficacy (9) 9
immunotherapy (9) 9
medical laboratory technology (9) 9
pharmacology/toxicology (9) 9
receptors, igg - genetics (9) 9
treatment outcome (9) 9
adalimumab (8) 8
analysis (8) 8
ankylosing-spondylitis (8) 8
antibodies, monoclonal - blood (8) 8
antibodies, monoclonal - therapeutic use (8) 8
chemotherapy (8) 8
dose-response relationship (8) 8
immune system diseases (8) 8
inflammatory-bowel-disease (8) 8
medicine & public health (8) 8
monoclonal-antibody (8) 8
polymorphism, genetic (8) 8
progression-free survival (8) 8
therapy (8) 8
young adult (8) 8
[ sdv.sp.pharma ] life sciences [q-bio]/pharmaceutical sciences/pharmacology (7) 7
abridged index medicus (7) 7
aged, 80 and over (7) 7
antirheumatic agents - blood (7) 7
antirheumatic agents - pharmacokinetics (7) 7
antirheumatic agents - therapeutic use (7) 7
drug therapy (7) 7
internal medicine (7) 7
retrospective studies (7) 7
[ sdv.can ] life sciences [q-bio]/cancer (6) 6
[ sdv.sp.med ] life sciences [q-bio]/pharmaceutical sciences/medication (6) 6
anti-cd20 monoclonal-antibody (6) 6
antibodies, monoclonal (6) 6
arthritis (6) 6
arthritis, rheumatoid - blood (6) 6
association (6) 6
bevacizumab (6) 6
care and treatment (6) 6
crohn disease - drug therapy (6) 6
disease-free survival (6) 6
drug monitoring (6) 6
half-life (6) 6
hematology (6) 6
immunoglobulin g (6) 6
immunology (6) 6
medication (6) 6
methotrexate (6) 6
pharmacogenetics (6) 6
research (6) 6
rheumatology (6) 6
rhumatology and musculoskeletal system (6) 6
safety (6) 6
trial (6) 6
[ sdv.mhep.rsoa ] life sciences [q-bio]/human health and pathology/rhumatology and musculoskeletal system (5) 5
adolescent (5) 5
antibodies, monoclonal, humanized - pharmacokinetics (5) 5
antibodies, monoclonal, humanized - therapeutic use (5) 5
antibodies, monoclonal, murine-derived (5) 5
antineoplastic agents - pharmacokinetics (5) 5
antirheumatic agents - administration & dosage (5) 5
biomarkers (5) 5
c-reactive protein - metabolism (5) 5
c-receptor polymorphisms (5) 5
cetuximab (5) 5
clinical trials (5) 5
colorectal cancer (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 03/2012, Volume 307, Issue 9, pp. 948 - 955
Journal Article
Journal Article
Therapeutic Drug Monitoring, ISSN 0163-4356, 08/2017, Volume 39, Issue 4, pp. 364 - 369
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 5/2015, Volume 54, Issue 5, pp. 551 - 562
Infliximab is a monoclonal anti-tumor necrosis factor-α (anti-TNFα) antibody that profoundly modified the treatment of Crohn’s disease (CD). The polymorphism... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology
Journal Article
Gastroenterology, ISSN 0016-5085, 2008, Volume 134, Issue 7, pp. 1861 - 1868
Background & Aims: The benefit to risk ratio of concomitant immunosuppressives with scheduled infliximab (IFX) maintenance therapy for Crohn's disease is an... 
Gastroenterology and Hepatology | RHEUMATOID-ARTHRITIS | ANTIBODIES | MULTICENTER | INFLAMMATORY-BOWEL-DISEASE | THERAPY | SERUM INFLIXIMAB | LYMPHOMA | RISK | INDUCTION | GASTROENTEROLOGY & HEPATOLOGY | SHORT-TERM | Azathioprine - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gastrointestinal Agents - administration & dosage | Crohn Disease - metabolism | Male | Intestinal Mucosa - drug effects | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Infliximab | Adult | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Female | Drug Therapy, Combination | France | Gastrointestinal Agents - pharmacokinetics | Immunosuppressive Agents - administration & dosage | Drug Administration Schedule | Mercaptopurine - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Belgium | Antibodies, Monoclonal - administration & dosage | Crohn Disease - pathology | Crohn Disease - drug therapy | Methotrexate - administration & dosage | Gastrointestinal Agents - adverse effects | Infusions, Intravenous | Intestinal Mucosa - pathology | Clinical trials | Crohn's disease | C-reactive protein | Tumor necrosis factor | Immunotherapy | Life Sciences | Human health and pathology | Hépatology and Gastroenterology
Journal Article
Journal Article
Journal Article
CANCER CHEMOTHERAPY AND PHARMACOLOGY, ISSN 0344-5704, 12/2016, Volume 78, Issue 6, pp. 1317 - 1318
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00280-016-3176-6 
LYMPHOMA | ANTIBODY | PHARMACOLOGY & PHARMACY | PARAMETERS | ONCOLOGY | POPULATION PHARMACOKINETICS | Biosimilar Pharmaceuticals - pharmacokinetics | Rituximab | Antimitotic agents | Antineoplastic agents | Resveratrol | Index Medicus
Journal Article
Journal Article